Tony Whitaker

1.4k total citations
36 papers, 1.0k citations indexed

About

Tony Whitaker is a scholar working on Infectious Diseases, Hepatology and Molecular Biology. According to data from OpenAlex, Tony Whitaker has authored 36 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Infectious Diseases, 21 papers in Hepatology and 12 papers in Molecular Biology. Recurrent topics in Tony Whitaker's work include HIV/AIDS drug development and treatment (22 papers), Hepatitis C virus research (20 papers) and HIV Research and Treatment (8 papers). Tony Whitaker is often cited by papers focused on HIV/AIDS drug development and treatment (22 papers), Hepatitis C virus research (20 papers) and HIV Research and Treatment (8 papers). Tony Whitaker collaborates with scholars based in United States, Belarus and France. Tony Whitaker's co-authors include Raymond F. Schinazi, Tamara R. McBrayer, Michaël Otto, Lieven Stuyver, Junxing Shi, Phillip M. Tharnish, Steven J. Coats, Kyoichi A. Watanabe, Longhu Zhou and Holly M. Micolochick Steuer and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Virology and Journal of Medicinal Chemistry.

In The Last Decade

Tony Whitaker

35 papers receiving 989 citations

Peers

Tony Whitaker
Tamara R. McBrayer United States
Tsuyoshi Adachi Japan
Michele Bosserman United States
Anne B. Eldrup United States
Stefania Lostia United States
Marija Prhavc United States
Julie Q. Hang United States
Maria Seifer United States
Olaf Weber Germany
Marc Bifano United States
Tamara R. McBrayer United States
Tony Whitaker
Citations per year, relative to Tony Whitaker Tony Whitaker (= 1×) peers Tamara R. McBrayer

Countries citing papers authored by Tony Whitaker

Since Specialization
Citations

This map shows the geographic impact of Tony Whitaker's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tony Whitaker with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tony Whitaker more than expected).

Fields of papers citing papers by Tony Whitaker

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tony Whitaker. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tony Whitaker. The network helps show where Tony Whitaker may publish in the future.

Co-authorship network of co-authors of Tony Whitaker

This figure shows the co-authorship network connecting the top 25 collaborators of Tony Whitaker. A scholar is included among the top collaborators of Tony Whitaker based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tony Whitaker. Tony Whitaker is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Whitaker, Tony, David G. Chapple, Rodney A. Hitchmough, Marieke Lettink, & G. B. Patterson. (2018). A new species of scincid lizard in the genus Oligosoma (Reptilia: Scincidae) from the mid-Canterbury high country, New Zealand. Zootaxa. 4377(2). 269–279. 4 indexed citations
2.
Zhou, Shaoman, Peng Liu, Longhu Zhou, et al.. (2017). 2′-Chloro,2′-fluoro Ribonucleotide Prodrugs with Potent Pan-genotypic Activity against Hepatitis C Virus Replication in Culture. Journal of Medicinal Chemistry. 60(13). 5424–5437. 19 indexed citations
3.
Tao, Sijia, Franck Amblard, Richard A. Stanton, et al.. (2015). Design, synthesis and evaluation of novel anti-HCV molecules that deliver intracellularly three highly potent NS5A inhibitors. Bioorganic & Medicinal Chemistry Letters. 25(17). 3711–3715. 2 indexed citations
4.
Schinazi, Raymond F., et al.. (2015). Synthesis and antiviral evaluation of 2′,3′-dideoxy-2′,3′-difluoro-D-arabinofuranosyl 2,6-disubstituted purine nucleosides. Heterocyclic Communications. 21(5). 315–327. 5 indexed citations
5.
Nettles, James H., Richard A. Stanton, Franck Amblard, et al.. (2014). Asymmetric Binding to NS5A by Daclatasvir (BMS-790052) and Analogs Suggests Two Novel Modes of HCV Inhibition. Journal of Medicinal Chemistry. 57(23). 10031–10043. 35 indexed citations
6.
Ibrahim, Mohamed A., MinKyun Na, Joonseok Oh, et al.. (2013). Significance of endangered and threatened plant natural products in the control of human disease. Proceedings of the National Academy of Sciences. 110(42). 16832–16837. 73 indexed citations
7.
Zhou, Longhu, Franck Amblard, Hongwang Zhang, et al.. (2013). Synthesis and evaluation of Janus type nucleosides as potential HCV NS5B polymerase inhibitors. Bioorganic & Medicinal Chemistry Letters. 23(11). 3385–3388. 7 indexed citations
8.
Pradère, Ugo, Peng Liu, Chengwei Li, et al.. (2013). Azetidines and spiro azetidines as novel P2 units in hepatitis C virus NS3 protease inhibitors. Bioorganic & Medicinal Chemistry Letters. 23(23). 6325–6330. 17 indexed citations
9.
Amblard, Franck, Hongwang Zhang, Longhu Zhou, et al.. (2013). Synthesis and evaluation of non-dimeric HCV NS5A inhibitors. Bioorganic & Medicinal Chemistry Letters. 23(7). 2031–2034. 21 indexed citations
10.
Roy, Vincent, Tamara R. McBrayer, Tony Whitaker, et al.. (2013). Synthesis and broad spectrum antiviral evaluation of bis(POM) prodrugs of novel acyclic nucleosides. European Journal of Medicinal Chemistry. 67. 398–408. 21 indexed citations
11.
Martínez‐Montero, Saúl, Susana Fernández, Yogesh S. Sanghvi, et al.. (2012). Synthesis, evaluation of anti-HIV-1 and anti-HCV activity of novel 2′,3′-dideoxy-2′,2′-difluoro-4′-azanucleosides. Bioorganic & Medicinal Chemistry. 20(23). 6885–6893. 25 indexed citations
12.
Shi, Junxing, Longhu Zhou, Franck Amblard, et al.. (2012). Synthesis and biological evaluation of new potent and selective HCV NS5A inhibitors. Bioorganic & Medicinal Chemistry Letters. 22(10). 3488–3491. 19 indexed citations
13.
Zhang, Hongwang, Longhu Zhou, Franck Amblard, et al.. (2012). Synthesis and evaluation of novel potent HCV NS5A inhibitors. Bioorganic & Medicinal Chemistry Letters. 22(14). 4864–4868. 11 indexed citations
14.
Costantini, Verónica, Tony Whitaker, Leslie Barclay, et al.. (2012). Antiviral Activity of Nucleoside Analogues against Norovirus. Antiviral Therapy. 17(6). 981–991. 58 indexed citations
15.
Courcambeck, Jérôme, et al.. (2011). 1210 GNS-227: A NEW POTENT AND SELECTIVE HCV NS3 PROTEASE INHIBITOR WITH A HIGH GENETIC BARRIER TO RESISTANCE. Journal of Hepatology. 54. S478–S478. 1 indexed citations
16.
Shi, Junxing, Longhu Zhou, Hongwang Zhang, et al.. (2011). Synthesis and antiviral activity of 2′-deoxy-2′-fluoro-2′-C-methyl-7-deazapurine nucleosides, their phosphoramidate prodrugs and 5′-triphosphates. Bioorganic & Medicinal Chemistry Letters. 21(23). 7094–7098. 16 indexed citations
17.
Zhang, Hongwang, Longhu Zhou, Steven J. Coats, et al.. (2011). Synthesis of purine modified 2′-C-methyl nucleosides as potential anti-HCV agents. Bioorganic & Medicinal Chemistry Letters. 21(22). 6788–6792. 13 indexed citations
18.
Zhang, Hongwang, Steven J. Coats, Franck Amblard, et al.. (2009). Synthesis and evaluation of 3′-azido-2′,3′-dideoxypurine nucleosides as inhibitors of human immunodeficiency virus. Bioorganic & Medicinal Chemistry Letters. 20(1). 60–64. 11 indexed citations
19.
Amblard, Franck, Emilie Fromentin, Mervi Detorio, et al.. (2009). Synthesis, antiviral activity, and stability of nucleoside analogs containing tricyclic bases. European Journal of Medicinal Chemistry. 44(10). 3845–3851. 8 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Tamara R. McBrayer Breakdown of academic impact, for papers by Tsuyoshi Adachi Breakdown of academic impact, for papers by Michele Bosserman Breakdown of academic impact, for papers by Anne B. Eldrup Breakdown of academic impact, for papers by Stefania Lostia Breakdown of academic impact, for papers by Marija Prhavc Breakdown of academic impact, for papers by Julie Q. Hang Breakdown of academic impact, for papers by Maria Seifer Breakdown of academic impact, for papers by Olaf Weber Breakdown of academic impact, for papers by Marc Bifano
Rankless by CCL
2026